Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO and Chairman of the Board of Directors & Founder Bertrand de Poly as Chief Strategy & Technology Officer
3.5.2023 20:04:00 EEST | Business Wire | Press release
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors. Founder Bertrand de Poly will assume the role of Chief Strategy & Technology Officer, focusing on strategy and technological development, along with his continued service on the board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230503005760/en/
F. Samuel Eberts III, Chief Executive Officer and Chairman of the Board of Directors (Photo: Business Wire)
This evolution in management aims to take the company to its next stage of growth, building on recent achievements including the acceptance of a clinical study manuscript with Johnson & Johnson at Boston University and Fox Chase Cancer Center, to be presented at the American Thoracic Society meeting in Washington, DC on May 19-24, 2023.
Samuel Eberts brings to Aquyre Biosciences decades of experience at the intersection of healthcare, law, and academia. His varied career includes equity partnership and board, and investment committee membership at a private equity firm whose collaboration with Harvard-affiliated Mass General’s Wellman Center facilitated world-class medical insights, and ongoing engagements as a Partner at Market Street HealthCare Partners, a private equity sponsor for healthcare investments. For 15 years, Sam was part of the senior management team at LabCorp, where he served as Chief Legal Officer, Corporate Secretary, and Senior Vice President of Corporate Affairs, with oversight of regulatory, government relations, and merger and acquisition activities. He is a senior advisor for healthcare investments to Aquyre’s shareholder, Invescore. Sam is also a Senior Lecturing Fellow at Duke University School of Law, a member of the advisory board for the Wilson Center, and has served on the World Policy Institute Advisory Board, the Harvard Law School Corporate Governance Forum, and the John F. Kennedy School of Government Healthcare Policy Leadership Council. He also serves on the board of several non-profit organizations.
“I am delighted that Samuel has agreed to help take Aquyre to the next level of its growth journey as we further refine our technology and scale our partner solutions and corporate operations. I look forward to working with him to help ensure the success of our company,” said Bertrand de Poly.
“I am particularly pleased that among the many shareholders of Aquyre, Canon Medical Systems Corporation, the medical equipment subsidiary of the optical, imaging, and industrial multinational Canon, Inc., is a strategic investor,” said Samuel Eberts. “I am honored to be leading such an impressive collection of people and products and am excited about the potential of Aquyre Biosciences. It is humbling and exciting to be part of an organization that will play an important role in healthcare. We are well positioned to bring a new level of precision in diagnosis of cancer, improving the lives of patients.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue assessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230503005760/en/
Contact information
Emily Ritacco
Director of Marketing
eritacco@aquyre.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BMC TV expands UK network for major sports broadcasts with Adtran and Fibre Technologies Ltd15.9.2026 15:00:00 EEST | Press release
Adtran today announced that BMC TV has expanded its UK core network, harnessing Adtran technology to support coverage of major events, including the FIFA World Cup and extensive racecourse broadcasting across the UK. The new infrastructure strengthens BMC TV’s packet edge, access and aggregation layers, enabling reliable distribution of live feeds across multiple locations with deterministic, low-latency performance. Designed to scale with growing broadcast demands, the network also provides a clear route to future 400Gbit/s services. The deployment was delivered in partnership with Fibre Technologies Ltd, which led solution design, commercial engagement and implementation support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915498940/en/ Adtran’s technology is helping BMC TV expand its core network to deliver live sporting events across the UK. “Live sports coverage places intense and constantly changing demands on ou
Two Powerhouses, One Drive: SharkNinja Joins McLaren Racing as Official Partner15.9.2026 15:00:00 EEST | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is proud to announce its new global partnership with McLaren Racing, the renowned British motorsport team, across its Formula 1, IndyCar, World Endurance Championship, and F1 Academy entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915026788/en/ As an Official Partner, SharkNinja will become part of the McLaren Racing ecosystem through exclusive experiences, content, and activations designed to connect fans with the ethos and innovation of the two brands. Through the McLaren Racing Accelerator Program, engineers from both companies will work together to apply advanced racing methodologies to the development of future SharkNinja products. “McLaren is one of the most decorated teams in motorsport history, built on a legacy of innovation, technical excellence, and performance at the highest level," said Mark Barrocas, Chief Executive Officer
The LYCRA Company Appoints Hua Du as Chief Executive Officer15.9.2026 15:00:00 EEST | Press release
The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, announced today that Hua Du has been appointed chief executive officer, effective September 14, as the company enters its next chapter following the successful completion of its financial restructuring. Du succeeds Dean Williams, who served as interim chief executive officer and will continue in his role as chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915565505/en/ The LYCRA Company Appoints Hua Du as Chief Executive Officer. With 30 years of leadership experience in the specialty chemical and biotechnology industries, Du is well positioned to lead the company into its next chapter. Du brings 30 years of leadership experience in the specialty chemical and biotech-based industries, driving transformational growth across global businesses. Du most recently served as CEO of
Ori Biotech Announces 10-year, $120M Partnership to Advance Automated Manufacturing for Commercial Cell Therapies15.9.2026 15:00:00 EEST | Press release
Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration with an undisclosed biopharmaceutical company to integrate the IRO® platform into a commercial cell therapy manufacturing process in a deal valued at up to $120M in services, milestones, equipment and consumable purchases over the next 10 years. The collaboration is designed to modernize the partner’s autologous cell therapy manufacturing infrastructure with the aim of expanding patient access to current and future potentially transformative cell therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915757436/en/ The IRO platform Autologous cell therapies, manufactured from a patient's own cells, require precise, reliable and scalable manufacturing processes. Meeting that requirement is essential to sustaining commercial availability and to rapidly bringing the next generation of
Riskified Brings Identity Risk Intelligence to Zendesk, Helping Retailers Stop Returns Fraud Without Sacrificing Customer Experience15.9.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today announced a new partnership with Zendesk that brings its Identity Risk Intelligence directly into Zendesk’s customer service workflow. The integration gives human and AI support agents real-time signals, helping retailers resolve legitimate claims faster while curbing returns and refund abuse that drains revenue. According to the National Retail Federation, U.S. retailers saw $849.9 billion in returns in 2025, approximately 9% of which were fraudulent. Based on those figures, Riskified calculates that return fraud costs U.S. retailers approximately $76.5 billion, and the losses are far higher when accounting for global returns fraud. Shoppers admit it too: one in four acknowledge wardrobing or bracketing, and roughly one in five admits to decoy returns, empty-box returns, or label tampering. For customer service teams, every claim carries the same dilemma: honor it and risk rewarding abuse
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom